Business
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
“On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone’s
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"“On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone’s Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of “On Track with HCM,” demonstrating the company’s long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart transplant. Experience the full interactive Multichannel News Release here: https://www.multivu.com/cytokinetics/9362952-en-cytokinetics-on-track-with-hcm Designed in collaboration with the HCM patient advocacy community to support HCM patients as they navigate their everyday lives with the burdensome symptoms of the disease, the program includes a website and eight original videos featuring Sydney and Willie who share their personal experiences. HCM affected the McLaughlin family for more than two decades before Willie received a heart transplant, while Sydney and the family supported him through his journey. This program reflects on their experiences to inspire others facing this disease. “On track or off, every journey has its hurdles,” said Sydney McLaughlin-Levrone. “Watching my father manage his health with the same rigor he once coached me as a child running track has been inspirational, and I am honored to join him in the ‘On Track with HCM’ campaign to help others stay motivated as they navigate life with this chronic condition.” HCM is the most common form of inherited heart disease, and it can affect people of any age. It is estimated that as many as 1 in every 350 people in the United States have HCM, but a large percentage of people are undiagnosed.1 People with HCM are at higher risk for developing atrial fibrillation, which can lead to blood clots, stroke, and other heart-related complications. HCM may also lead to heart failure or sudden cardiac arrest. “Cytokinetics is committed to supporting people living with HCM by addressing not only the clinical aspects of care but the human experience behind the disease,” said Diane Weiser, Cy...